Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of baicalin and medication of chemical treatment in platinum family

The technology of a chemotherapy drug, baicalein, applied in the combined field of baicalein and platinum chemotherapy drugs

Inactive Publication Date: 2007-02-21
吴一心
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0020] So far, there is no report about the synergistic effect of baicalin and chemotherapy drugs on anti-tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of baicalin and medication of chemical treatment in platinum family
  • Combination of baicalin and medication of chemical treatment in platinum family

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1 The synergistic effect of baicalin on paclitaxel in resisting liver cancer cells

[0046] Human liver cancer cell line HepG2, the cell line was suspended in the cell culture medium containing 10% (small) bovine fetal serum, and 5 × 10 3 / well seeded in 96-well cell culture dishes. After culturing for 24 hours, baicalin was added and mixed with paclitaxel in different molar concentration ratios into the culture medium. Final concentration: baicalin 0.3-200 μg / ml, paclitaxel: 0.8ng-0.1 μg / ml. MTT was measured after further culturing for 72 hours. Stained with tetrazolium salt (MTT) method and calculated the inhibition rate of HepG2 proliferation when baicalein and paclitaxel were used alone or in combination, and analyzed data with CalcuSyn statistical software and combined drug index (CI) method.

[0047] See Table 1 for the HepG2 cell proliferation inhibitory rate and combined drug index values ​​when used alone or in combination:

[0048] Singl...

Embodiment 2

[0052] Example 2 The synergistic effect of baicalin on paclitaxel in anti-lung cancer cells

[0053] Human lung cancer cell line A549, the cell line was suspended in the cell culture medium containing 10% (small) bovine fetal serum, and 5 × 10 3 / well seeded in 96-well cell culture dishes. After culturing for 24 hours, baicalin was added and mixed with paclitaxel in different molar concentration ratios into the culture medium. Final concentration: baicalin 0.3-200 μg / ml, paclitaxel: 0.8ng-0.1 μg / ml. MTT was measured after further culturing for 72 hours. Stained with tetrazolium salt (MTT) method and calculated the inhibitory rate of A549 proliferation when baicalein and paclitaxel were used alone or in combination, and analyzed data with CalcuSyn statistical software and combined drug index (CI) method.

[0054] The inhibition rate of A549 cell proliferation when the drug is used alone or in combination, and the value of the combination drug index are shown in Table 3:

[...

Embodiment 3

[0059] Example 3 The synergistic effect of baicalin on paclitaxel on anti-colorectal cancer cell lines

[0060] Human colorectal cancer cell line HCT116, the cell line was suspended in the cell culture medium containing 10% (small) bovine fetal serum, and 5 × 10 3 / well seeded in 96-well cell culture dishes. After culturing for 24 hours, baicalin was added and mixed with paclitaxel in different molar concentration ratios into the culture medium. Final concentration: baicalin 0.3-200 μg / ml, paclitaxel: 0.8ng-0.1 μg / ml. MTT was measured after further culturing for 72 hours. Stained with tetrazolium salt (MTT) method and calculated the inhibitory rate of HCT116 proliferation when baicalin and cisplatin were used alone or in combination, and analyzed data with CalcuSyn statistical software and combined drug index (CI) method.

[0061] The inhibition rate of HCT116 cell proliferation when the drug is used alone or in combination, and the combined drug index value are shown in Ta...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An application of scutelloside along with a Pt-type chemicotherapeutic medicine including carboplatin and taxol in preparing the medicine for treating tumor is disclosed. A resultant composite medicine is also disclosed.

Description

technical field [0001] The invention relates to a composition composed of a flavonoid compound and a platinum chemotherapeutic drug for antitumor; the invention also relates to the use of the compound in preparing medicine for treating tumor. Background technique [0002] "Chemotherapy" is an abbreviation for "chemotherapy". The current concept of chemotherapy is generally understood as "tumor chemotherapy", that is, the method of using anti-tumor chemotherapy drugs and adopting certain measures and programs to treat tumors. Among them, "platinum-based anti-tumor chemotherapeutic drugs" have a similar anti-tumor mechanism: the main target is located in DNA, which can destroy DNA replication by forming intra-strand cross-links, inter-strand cross-links, and DNA-protein cross-links. and inhibition of cell division to inhibit the growth of tumor cells. The common ones are: cisplatin (CDDP), carboplatin (carboplatin), oxaliplatin (oxaliplatin, L-OH), nedaplatin (nedaplatin), l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K31/337A61K31/282A61K31/555A61P35/00
Inventor 吴一心
Owner 吴一心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com